Compare Recursion Pharmaceuticals Inc (RXRX) vs Union Pacific Corporation (UNP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Union Pacific Corporation — how do they compare? Recursion Pharmaceuticals Inc trades at $3.24 (market cap $1.86B), while Union Pacific Corporation trades at $285.05 (market cap $171.36B). The key difference: Union Pacific Corporation is far larger — about 92.1× Recursion Pharmaceuticals Inc's market cap, and Union Pacific Corporation pays a 1.97% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | UNP | |
|---|---|---|
Market Cap | $1.86B | $171.36B |
Sector | Health | Industrials |
52-Week High | $6.79 | $310.62 |
52-Week Low | $2.84 | $214.91 |
Enterprise Value | $1.38B | $200.42B |
Dividend Yield | — | 1.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Union Pacific (UNP) trades at $288.45, down 0.4% on the day, with a bearish technical signal but strong fundamentals including a 28.85% net income margin and robust cash flow. Recent earnings beats in Q1 and Q2 2026, coupled with a pending Norfolk Southern merger expected to close by late 2027, highlight growth potential. The stock is supported by a consensus analyst price target of $334.33, indicating 16% upside.
The outlook is positive due to solid profitability and merger prospects, but risks include regulatory hurdles for the merger and economic sensitivity. Analysts are predominantly bullish (58.7% buy ratings), though technical indicators suggest near-term caution with support at $287.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →
